The point-of-care test will use the companies' respective technologies and detect two protein biomarkers of inflammation and immune system activity.
The "drug-tolerant assay" found that only very early TNF levels offered treatment response clues in RA patients treated with the TNF inhibitor adalimumab.
ProAxsis and a US-based biotechnology company codeveloped the assay as part of an ongoing collaboration. ProAxsis has made its first commercial sale of the test.
Ortho said it will initially launch Sentinel's wide-range C-reactive protein assay in North America, Europe, Africa, and the Middle East.
FlowMetric said that by combining products, the partners will provide consumers with data security and the ability to govern how their personal information is shared, utilized, and monetized.
Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.
The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.
The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.
The researchers, led by VIB and Ghent University in Belgium, hope to complete a validation study within a year.